Two Organizations To Support Wave Life Sciences’ FTD, ALS Program
The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) will support Wave Life Sciences Ltd's (NASDAQ: WVE) amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) program.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year.
How Good Are WAVE Life Sciences’s Earnings? | Return On Capital Employed
According to data from Benzinga Pro, during Q3, WAVE Life Sciences's (NASDAQ:WVE) reported sales totaled $36.42 million. Despite a 80.9% increase in earnings, the company posted a loss of $7.61 million.
WAVE Life Sciences Q3 EPS $(0.12) Beats $(0.63) Estimate, Sales $36.42M Up From $3.45M YoY
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.63) by 80.95 percent. This is a 86.05 percent increase over losses of $(0.86) per share from
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Wave Life Sciences, Takeda Discontinue Research On Preclinical CNS Programs
Wave Life Sciences Ltd (NASDAQ:WVE) has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited (NYSE:TAK) to discontinue discovery & research of preclinical…